[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tachycardia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tachycardia":400},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,47,83,127,149,176,204,233,266,289,318,345,366],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100623159",false,"NCT07393009","BIO|STREAM.CSP Study","Observation of Clinical Routine Care for Patients Implanted With BIOTRONIK Devices Used for Conduction System Pacing (CSP)","Inclusion Criteria:\n\n* Guideline indication for pacemaker or cardiac resynchronization therapy with or without defibrillation function (CRT-P\u002F-D)\n* Patient is intended for a de novo implantation and LBBAP therapy with an investigational generator and an investigational lead OR has just been implanted with an investigational generator and an investigational lead positioned permanently deep within the intraventricular septum and has not yet been discharged from the hospital OR transitions from the BIO\\|MASTER.CSP study\n* Ability to understand the nature of the study\n* Ability and willingness to perform all follow-up visits\n* Ability and willingness to use the CardioMessenger and acceptance of the BIOTRONIK Home Monitoring concept\n\nExclusion Criteria:\n\n* Planned dation from intended use\n* Planned for cardiac surgical procedures, heart transplantation or interventional measures other than the study procedure within one year after enrollment\n* Life-expectancy less than 12 months\n* Pregnant or breast feeding\n* Age less than 18 years\n* Participation in an interventional clinical investigation, except for submodules within this study.","ALL","18 Years",{"count":18,"type":19},1000,"ESTIMATED","4 Years","OBSERVATIONAL","The registry is designed to assess outcome, performance and residual safety aspects of BIOTRONIK products which are used in the context of CSP based on long-term data from an unselected, real-life clinical set-up.",[24,25,26,27,28,29,30],"Cardiac Pacing","Cardiac Pacemaker","Implantable Cardioverter Defibrillator","Cardiac Resynchronization Therapy Devices","Bradycardia","Tachycardia","Heart Failure",[32,33],"Conduction system pacing (CSP)","Left bundle branch area pacing (LBBAP)","RECRUITING","2026-06-24",{"date":37,"type":38},"2026-06-29","ACTUAL",{"date":40,"type":38},"2026-05-25",{"date":42,"type":19},"2033-02-01",{"name":44,"class":45},"Biotronik SE & Co. KG","INDUSTRY",40,{"id":48,"slug":4,"hasResults":10,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":67,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":82},"100635703","NCT07556133","Dexmedetomidine and Propofol for Sedation in Cataract Surgery.","Dexmedetomidine vs Propofol for Sedation in Cataract Surgery : a Prospective Randomized Controlled Trial.","Inclusion Criteria:\n\n* Adults undergoing cataract surgery\n\nExclusion Criteria:\n\n* Severe hepatic insufficiency\n* Third degree AV block\n* Patient refusal",{"count":18,"type":19},"INTERVENTIONAL",[56],"NA","The goal of this prospective, randomized, single-blinded is to learn if there is an ideal sedation protocol in cataract surgery in adults.\n\nThe main questions it aims to answer are:\n\n* Does the combination of Dexmedetomidine and Propofol affect significantly Ramsay sedation scale, compared to Dexmedetomidine and compared to Propofol?\n* How does each sedation protocol affect hemodynamics? (Heart rate and blood pressure)\n* Are respiratory events more common in a certain group?\n* Is the surgeon's satisfaction similar among groups?\n* Are adverse effects (bradycardia, hypotension, nausea) more common in a certain group?\n\nResearchers will compare 3 sedation protocols : Dexmedetomidine versus Propofol versus the combination of these 2 drugs and to see if one protocol is overall superior to the others. Fentanyl will also be used in all 3 sedation protocols.\n\nParticipants will :\n\n* Receive one of these three protocols\n* Be operated for one or both eyes\n* Monitored during the whole surgery and in the recovery room\n* Be evaluated by the Ramsay sedation scale by a trained Anesthesiologist or CRNA during surgery and in the recovery room Surgeons will be asked about how much they were satisfied.",[59,60,61,62,63,64,65,28,29,66],"Sedation","Cataract","Hemodynamic","Hemodynamic Changes","Dexmedetomidine","Propofol Dosage","Fentanyl","Nausea and Vomiting",[68,60,69,70,71],"Dexmedetomidine and propofol in cataract surgery","sedation","Dexmedetomidine in cataract surgery","Sedation for cataract surgery","2026-04-21",{"date":74,"type":38},"2026-04-29",{"date":76,"type":38},"2025-11-09",{"date":78,"type":19},"2026-12-09",{"name":80,"class":81},"Saint-Joseph University","OTHER",1,{"id":84,"slug":4,"hasResults":10,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":89,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":90,"targetDuration":91,"studyType":21,"phases":4,"briefSummary":92,"conditions":93,"keywords":106,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":4},"100630769","NCT07491978","Development and Multicenter Validation of an AI-Based Remote Photoplethysmography (rPPG) Facial Scan for Multimodal Health Assessment","Development and Multicenter Validation of an AI-Based Remote Photoplethysmography (rPPG) Facial Scan for Multimodal Health Assessment: Agreement With Clinical, Laboratory, and Psychological Parameters in an Urban Population","Inclusion Criteria:\n\n1. Adults aged ≥18 years.\n2. Able and willing to provide written informed consent.\n3. Able to comply with study procedures, including face scan, physical examination, blood sampling, and questionnaire completion.\n4. Clinically stable at the time of assessment.\n\nExclusion Criteria:\n\n1. Facial conditions affecting the region of interest (ROI), such as injury, deformity, or impaired circulation, that may interfere with rPPG signal acquisition.\n2. Presence of facial tattoos or coverings that obstruct optical signal detection.\n3. Inability to remain still or comply with measurement procedures during data acquisition.\n4. Severe medical conditions that preclude safe participation, as judged by the investigator.\n5. Incomplete data or withdrawal of consent during the study.\n\n   \\-",true,{"count":18,"type":19},"1 Day","The goal of this observational study is to learn if a non-contact facial scan using artificial intelligence (AI) can be used to check health status in adults living in urban areas such as Jakarta. The facial scan uses a method called remote photoplethysmography (rPPG), which measures small changes in blood flow from the face using a camera.\n\nThe main questions this study aims to answer are:\n\n1. How close are the results from the facial scan to standard medical measurements, such as heart rate, breathing rate, blood pressure, and oxygen levels?\n2. Can the facial scan estimate other health indicators, such as blood sugar, lipid profile, HbA1c, and hemoglobin levels?\n3. Is there a relationship between the facial scan results and mental health, such as stress, anxiety, and depression?\n\nParticipants will take part in several simple and mostly non-invasive procedures:\n\n1. Answer questionnaires about their mental health and daily habits\n2. Have basic health checks, such as blood pressure, heart rate, and body measurements\n3. Provide a blood sample for laboratory testing\n4. Complete a facial scan using a camera for about 1 to 3 minutes\n\nResearchers will compare the results from the facial scan with standard clinical and laboratory tests to see how well the technology works.\n\nThis study may help develop a simple and accessible screening tool that can be used for early detection of health risks. It may also support the use of digital health and telemedicine in community and clinical settings.",[94,95,96,29,97,98,99,100,101,102,103,104,105],"Metabolic Syndrome","Hypertension","Diabetes (DM)","ASCVD","Depression Disorder","Anxiety","Stress (Psychology)","Obesity & Overweight","Cardiometabolic Risk Factors","Cardiometabolic Health Indicators","Sleep","Wellness",[107,108,109,110,111,112,113,114,115,116],"remote photoplethysmography","rPPG","artificial intelligence","digital biomarker","telemedicine","vital signs","cardiometabolic risk","machine learning","facial scan","screening tool","NOT_YET_RECRUITING","2026-04-15",{"date":120,"type":38},"2026-04-20",{"date":122,"type":19},"2026-04-24",{"date":124,"type":19},"2027-03-30",{"name":126,"class":81},"Tarumanagara University",{"id":128,"slug":4,"hasResults":10,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":89,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":133,"targetDuration":91,"studyType":21,"phases":4,"briefSummary":135,"conditions":136,"keywords":4,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":82},"100631485","NCT07501299","HeartBeam ECG Registry","Collection of ECG Recordings Using the HeartBeam 3-Lead ECG Recorder","Inclusion Criteria:\n\nUndergoing ECG as part of standard of care Able and willing to provide written informed consent\n\nExclusion Criteria:\n\nOpen chest wounds or surgery to the chest or abdomen within 30 days Inability to complete ECG acquisition with either HeartBeam device or standard 12-L ECG Unstable condition where registry participation may interfere with care",{"count":134,"type":19},600,"The HeartBeam ECG Registry will collect ECG recordings acquired with the HeartBeam System with relevant clinical information in clinical settings.",[137,138,28,29,139],"Atrial Fibrillation","Atrial Flutter","Arrhythmia","2026-03-24",{"date":142,"type":38},"2026-03-30",{"date":144,"type":19},"2026-03",{"date":146,"type":19},"2028-12",{"name":148,"class":45},"HeartBeam, Inc.",{"id":150,"slug":4,"hasResults":10,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":156,"targetDuration":158,"studyType":21,"phases":4,"briefSummary":159,"conditions":160,"keywords":163,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":175},"100368267","NCT04075084","Observation of Clinical Routine Care for Patients With BIOTRONIK Implantable Cardiac Monitors (ICMs)","BIO|STREAM.ICM: Observation of Clinical Routine Care for Patients With BIOTRONIK Implantable Cardiac Monitors (ICMs)","BIOSTREAM-ICM","Inclusion Criteria:\n\n* Patient is intended to receive a BIOTRONIK Implantable Cardiac Monitor (ICM)\n* Patient is able to understand the nature of the registry and to provide written informed consent.\n* Patient is willing and able to use the CardioMessenger and accepts the BIOTRONIK Home Monitoring concept.\n\nExclusion Criteria:\n\n* Patient is pregnant or breast feeding.\n* Patient is less than 18 years old.\n* Patient is participating in another interventional clinical investigation other than the submodules of BIO\\|STREAM.ICM",{"count":157,"type":19},1400,"3 Years","This registry is performed for the long-term assessment of outcome, performance and residual safety aspects of the BIOMONITOR III and possible successors in a real-life clinical set-up. In addition, this registry is set up in a way that it may also be used as a platform for submodules to investigate additional scientific and regulatory aspects while minimizing the additional effort for the investigational sites and patients.",[29,137,161,28,162],"Syncope","Cryptogenic Stroke",[164,165,166],"Implantable Cardiac Monitor","BIOMONITOR III","BIOMONITOR IV","2025-09-26",{"date":169,"type":38},"2025-10-01",{"date":171,"type":38},"2019-10-28",{"date":173,"type":19},"2027-08-30",{"name":44,"class":45},31,{"id":177,"slug":4,"hasResults":10,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":181,"eligibilityCriteria":182,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":54,"phases":185,"briefSummary":187,"conditions":188,"keywords":192,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":82},"100419981","NCT04748796","Comparison of Landiolol Versus Standard of Care for Prevention of Mortality in Patients Hospitalized for a Septic Shock With Hypercontractility","Comparison of Landiolol Versus Standard of Care for Prevention of Mortality in Patients Hospitalized for a Septic Shock With Hypercontractility: an Open Label Prospective Randomized Study","HyperBetashock","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Patient admitted for a septic shock (according to the SEPSIS3 definition: sepsis with persisting hypotension (MAP\\\u003C65mmHg or SAP \\\u003C90mmHg) requiring vasopressors to maintain MAP\\>65mmHg and having a serum lactate level \\>2 mmol\u002FL\n* Patient who received at least 30ml\u002Fkg of fluid and absence of fluid responsiveness\n* Left ventricular ejection fraction \\>65% (visual or Simpson method using echocardiography)\n* Tachycardia \\>100 bpm in sinus rhythm with a MAP 65mmHg for more than 1 hour\n* Patient receiving invasive mechanical ventilation\n* Patients adapted to the ventilator under sedation and analgesia\n* Written informed consent\n* Patient covered by French national health insurance\n\nExclusion Criteria:\n\n* Patients with inclusion criteria already present for more than 36 hours\n* Patient treated with Dobutamine, adrenaline or isoprenaline\n* Patient currently treated with beta blockers (previous home betablocker treatment is not an exclusion criteria)\n* Supra ventricular (atrial fibrillation or flutter) or ventricular arrhythmias\n* Patients with any form of cardiac pacing\n* Sick sinus syndrome\n* Severe atrioventricular (AV) nodal conductance disorders (without pacemaker): 2nd or 3rd degree AV block\n* Known pulmonary hypertension\n* ScVO2 \\\u003C70%\n* Moribund\n* Cardiac arrest\n* Non-treated phaeochromocytoma\n* Acute asthmatic attack\n* Pregnant or breastfeeding woman\n* Patient deprived of liberty by administrative or judicial decision or placed under judicial protection (guardianship or supervision),\n* Age \\\u003C18 years\n* Hypersensitivity to the active substance or to any of the excipients\n* Severe bradycardia (less than 50 beats per minute)\n* Cardiogenic shock\n* Severe hypotension\n* Decompensated heart failure when considered not related to the arrhythmia\n* Severe, uncorrectable metabolic acidosis\n* Presence of significant bleeding, or\n* Acute respiratory distress defined by increased oxygen dependency, polypnea \\> 30 \u002Fmin, signs of struggle (pulling, thoraco-abdominal sway) if the patient is not intubated and ventilated.",{"count":184,"type":19},360,[186],"PHASE3","Several data emphasize the relation between tachycardia (\\>90\u002Fmin) and high mortality during septic shock. The investigators previously demonstrated the high mortality associated with hypercontractility, tachycardia and the presence of a left ventricular obstruction. A severe hypovolemia, a hyper adrenergic stimulation or a severe vasoplegia can all explain this relation between tachycardia, hypercontractility and the mortality during septic shock.\n\nLandiolol is another short-term acting beta-blocker with a half-life of 4 minutes without any beta 2 activity or membrane stabilizing effect. The landiolol has been used in critically ill patients to control supraventricular tachycardia but not in this context of tachycardia and septic shock. The investigators hypothesize that landiolol by reducing the heart rate may improve the survival of patients treated for a septic shock and presenting with an hypercontractility state.",[189,29,190,191],"Septic Shock","Mortality During Septic Shock","Beta-blocker",[189,29,193,194],"mortality during septic shock","beta-blocker","2025-08-19",{"date":197,"type":38},"2025-08-24",{"date":199,"type":38},"2021-02-01",{"date":201,"type":19},"2027-09",{"name":203,"class":81},"Centre Hospitalier Universitaire, Amiens",{"id":205,"slug":4,"hasResults":10,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":54,"phases":213,"briefSummary":214,"conditions":215,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":82},"100554740","NCT06503016","The Effect of phoSPHocreatine on mEdical Emergency Team (Met) tREated Patients","The Effect of phoSPHocreatine on mEdical Emergency Team (Met) tREated Patients: a Randomized Clinical Trial Protocol","SPHERE","Inclusion Criteria:\n\n1. Admitted in hospital (but outside ICU)\n2. Age\\>=18 years\n3. Written informed consent\n4. Serum creatinine \\\u003C=2 mg\u002Fdl\n5. Patient with impending or underlying cardiac failure or cardiac arrest, irrespectively of the primitive organ failure, and the Medical Emergency Team (MET) is called upon at least one of the following:\n\n   1. Threatened airways;\n   2. Respiratory arrest;\n   3. Respiratory rate \\\u003C5 or \\>36 breaths per min;\n   4. Pulse rate \\\u003C40 or \\>140 beats per min;\n   5. Systolic blood pressure \\\u003C 90 mm Hg;\n   6. Sudden fall in level of consciousness;\n   7. Fall in Glasgow coma scale of \\> 2 points.\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years;\n2. Ongoing cardiac massage;\n3. Current hospital admission from a care nursing facility;\n4. Planned discharge to a care nursing facility;\n5. Reasons for withdrawal of life-sustaining therapy;\n6. History of kidney transplantation;\n7. Solitary kidney (by any reason);\n8. Serum Creatinine \\> 2 mg\u002Fdl;\n9. Immediate need for ICU admission;\n10. Known allergy to PCr;\n11. Pregnancy;\n12. Previous enrollment and randomization into this trial;\n13. Administration of PCr in the previous 30 day.",{"count":212,"type":19},400,[186],"Unexpected deaths and unplanned intensive care unit (ICU) admissions are common during hospital stay and are often preceded by warning abnormalities in patients' vital signs. These abnormalities trigger Medical Emergency Team (MET) activation and up to 15% of patients visited by the MET is admitted to the ICU with an overall hospital stay after the MET intervention of approximately 2 weeks. Phosphocreatine (PCr) is a natural energy-buffering molecule associated with signals of mortality reduction in patients with acute cardiac conditions (according to meta-analytic finding from our group) and with encouraging beneficial effects on other acute organ failures (e.g. brain). The investigators designed a multi-center, randomized, placebo-controlled trial to confirm the promising beneficial effects of PCr in hospitalized patients. The investigators expects a reduction in hospital stay (measured as an increase in days alive and out of hospital at 30 days) when PCr is added to standard treatment in patients requiring MET intervention.",[216,217,218,219,220,221,29,28,222,223],"Hypotension","Consciousness, Level Altered","Airway Disease","Respiratory Failure","Tachypnea","Bradypnea","Cardiac Failure","Cardiac Arrest","2025-08-05",{"date":226,"type":38},"2025-08-06",{"date":228,"type":38},"2024-10-08",{"date":230,"type":19},"2026-07",{"name":232,"class":81},"Università Vita-Salute San Raffaele",{"id":234,"slug":4,"hasResults":10,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":238,"eligibilityCriteria":239,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":54,"phases":242,"briefSummary":243,"conditions":244,"keywords":250,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":265},"100594377","NCT07018648","Clinical Safety and Efficacy Testing of a Medical Device Kardi Ai, an ECG Telemetry Monitoring System","Clinical Safety and Efficacy Testing of a Medical Device Kardi Ai, an ECG Telemetry Monitoring System Using Artificial Intelligence to Evaluate ECGs Measured by Hardware Component (POLAR H10 Chest Strap)","Kardi Ai","Inclusion Criteria:\n\n* Age above 18 years\n* Signed informed consent\u002Fwillingness to cooperate\n* Confirmed or suspected heart rhythm disorder of a cardiac rhythm disorder\n* Ability to use a smartphone and mobile app Kardi Ai\n* The subject's mobile phone meets the minimum requirements for the Kardi Ai app to work\n\nExclusion Criteria:\n\n* Confirmed pregnancy\n* Allergic reactions to standard substances used in manufacture of clothing or other textiles\n* Superficial wound or skin irritation at the site of the chest belt attachment",{"count":241,"type":19},115,[56],"The goal of this clinical trial is to evaluate the safety and efficacy of medical device Kardi Ai, an ECG telemetry monitoring device in adult population.\n\nThe main questions it aims to answer are:\n\n* What is the sensitivity and specificity of Kardi Ai device for all monitored heart rythm disorders (combined)\n* What is the sensitivity and specificity of Kardi Ai device for each of the monitored heart rythm disorders\n* What is the quality of the ECG recordings\n\nParticipants will receive Kardi Ai medical device. They will use it to collect ECG recordings from at least 5 different days and in total collect records of at least 10 hours duration.",[245,246,247,28,29,248,249],"Atrial Fibrillation (AF)","Atrial Premature Complexes","Ventricular Premature Complexes","Supraventricular Tachycardia","Wide QRS Tachycardia",[251,252,253,254,255],"AI","heart rhythm disorders","ECG","EKG","atrial fibrillation","2025-06-10",{"date":258,"type":38},"2025-06-12",{"date":260,"type":38},"2025-05-19",{"date":262,"type":19},"2025-08-30",{"name":264,"class":45},"KARDI AI Technologies s.r.o.",2,{"id":267,"slug":4,"hasResults":10,"nctId":268,"briefTitle":269,"officialTitle":269,"acronym":270,"eligibilityCriteria":271,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":272,"targetDuration":4,"studyType":54,"phases":274,"briefSummary":275,"conditions":276,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":265},"100565109","NCT06637904","TriVerity™ for Improved Management of Emergency Department (ED) Patients With Suspected Infections","TIMED","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Participant presents to ED with ALL of the below:\n\n   2.1. Suspected acute infection (e.g., respiratory, urinary, abdominal, skin \\& soft-tissue infection, meningitis\u002Fencephalitis, or any other infection), and 2.2. Either heart rate \\>100 beats per minute or\u002Fand temperature \\>38C. 2.3. NOT immediately roomed in a primary designated treatment location,( i.e., they can be in the waiting room, ED triage hallways, and\u002For ED staging area\u002Ffast track area).\n3. Able to provide informed consent, or consent by legally authorized representative.\n4. Reachable via confirmed working cell phone (with backup contact number) and willing to respond to follow-up safety checks (see below for details).\n\nExclusion Criteria:\n\n1. Patient-reported treatment with systemic antibiotics, systemic antiviral agents or systemic antifungal agents within the past 7 days prior to presentation in the waiting room of the ED. Participants will not be excluded for use of:\n\n   1. Antiviral treatment for chronic viral infections, i.e., HIV, hepatitis B and hepatitis C\n   2. Topical antibiotics, topical antivirals or topical antifungal agents\n   3. Anti-herpes prophylaxis aiding suppression of a recuring herpes infection\n   4. Single dose of one or combination of peri-operative (prophylactic) antibiotics\n2. Patients receiving palliative or hospice care, or those receiving limited interventional care (see Appendix B).\n3. Prisoners, mentally disabled, or unable to give consent. Should the patient not be able to provide informed consent the legally authorized representative can provide the consent on behalf of the patient.\n4. Participants receiving experimental therapy or already enrolled in an interventional clinical trial in which a subject receives some type of intervention, which can include but is not limited to investigational drugs, medical devices, or vaccines. Participants that are enrolled in non-interventional or observational clinical trials will be allowed to participate in this clinical trial.\n5. Participants previously enrolled in the present clinical trial.",{"count":273,"type":19},300,[56],"A pre\u002Fpost interventional use trial, with ED patients who are initially triaged to locations other than a dedicated patient room in the main ED (e.g., waiting room, hallway bed, and\u002For the staging area\u002Ffast track area) with suspected infection and tachycardia or fever will be enrolled. Study conduct will be performed under an Investigational Device Exemption (IDE) from the Food and Drug Administration (FDA). Participants in the pre-phase, treated with standard of care, will be gathered from a retrospective database using propensity matching, whereas participants in the post-phase will be managed incorporating the TriVerity™ Acute Infection and Sepsis Test results with standardized guidance for interpretation and resulting management actions. Many outcomes will be captured and compared between the pre- and post-phase phases including sepsis bundle compliance, patient disposition, appropriate use of antimicrobials (antibiotics and antivirals) and health economic findings. Safety measures for participants in the post-phase will include patient follow-up at predefined time points. The objective is to demonstrate improvement of patient management when incorporating the TriVerity Test result compared to standard of care. Improvements based on diagnostic (bacterial vs viral vs non-infectious inflammation) and prognostic (need for 7-day ICU level care) readouts of the TriVerity Test result will be tracked.",[277,278,29,279],"Sepsis","Infections","Fever","2025-01-06",{"date":282,"type":38},"2025-01-08",{"date":284,"type":38},"2024-11-08",{"date":286,"type":19},"2025-03-31",{"name":288,"class":45},"Inflammatix",{"id":290,"slug":4,"hasResults":10,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":10,"sex":15,"minAge":295,"maxAge":4,"enrollmentInfo":296,"targetDuration":4,"studyType":54,"phases":298,"briefSummary":299,"conditions":300,"keywords":302,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":310,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":316,"locationsCount":4},"100558048","NCT06546046","Analysis of the Efficacy and Stability of a Wearable ECG Monitor","Analysis of the Efficacy and Stability of a Single-Channel Patch-Type Wearable Electrocardiogram Monitor","Inclusion Criteria:\n\n1. Adults aged 19 years or older\n2. Patients admitted to Chonnam National University Hospital who require ECG monitoring\n3. Individuals who have expressed their intention to participate in this study or have obtained written consent from a proxy\n\nExclusion Criteria:\n\n1. Individuals who are unable to provide consent themselves or through a legally designated representative\n2. Individuals deemed unsuitable for participation in the clinical trial based on the researcher's judgment","19 Years",{"count":297,"type":19},100,[56],"This study aims to analyze the efficacy and safety of wearable electrocardiogram (ECG) monitoring by simultaneously attaching a single-channel patch-type wearable ECG monitoring device (HiCardi+ by Mezoo Co., Ltd.) and a telemetry device (IntelliVue MX40 by Philips) used in actual wards to patients prescribed with ECG monitoring",[301,28,29,137,138,247],"Arrhythmias, Cardiac",[303,304,305,306,307,308],"Monitoring","Telemetry","Wearable device","Arrhythmia alarm","Signal loss","Satisfaction survey","2024-08-11",{"date":311,"type":38},"2024-08-14",{"date":313,"type":19},"2024-09-09",{"date":315,"type":19},"2025-03-30",{"name":317,"class":81},"Mezoo Co., Ltd.",{"id":319,"slug":4,"hasResults":10,"nctId":320,"briefTitle":321,"officialTitle":322,"acronym":4,"eligibilityCriteria":323,"healthyVolunteers":89,"sex":15,"minAge":16,"maxAge":324,"enrollmentInfo":325,"targetDuration":4,"studyType":54,"phases":326,"briefSummary":327,"conditions":328,"keywords":332,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":82},"100554944","NCT06505668","Effect of Atenolol Versus Ivabradine on HRV in TRS Patients on Clozapine With Tachycardia: A Randomised Control Trial.","Effect Of Atenolol Versus Ivabradine On Heart Rate Variability In Treatment Resistant Schizophrenia Patients On Clozapine With Tachycardia: A Randomized Control Trial.","Inclusion Criteria:\n\nAll patients coming for treatment at the Out-patient department and In-patient department of the Department of Psychiatry fulfilling the following are included:\n\n1. Patients diagnosed with TRS (TRRIP consensus) receiving clozapine.\n2. Aged between 18 to 60 years of either sex\n3. Having baseline heart rate of \\>100\u002Fminute.\n4. Written informed consent from Legally Authorized representative.\n\nExclusion Criteria:\n\nPatients with any one of the following are excluded from the study:\n\n1. Already receiving Atenolol or Ivabradine.\n2. Patients having any contraindication to using Atenolol or Ivabradine.\n3. Receiving any other medication other than Clozapine known to cause autonomic dysregulation.\n4. Active substance use.\n5. Serious medical or neurological comorbidity.","60 Years",{"count":46,"type":19},[56],"Clozapine is the only drug approved for Treatment Resistant Schizophrenia. However, it has been associated with many adverse drug reactions including agranulocytosis, myocarditis, sialorrhea, constipation, orthostasis, tachycardia. There are many factors that have impacted the use of clozapine in TRS patients including physician hesitation, patient denial, stopping of drug due to Adverse drug reactions.\n\nAlthough Tachycardia should not be the reason to stop clozapine, but data shows that it leads to discontinuation of drugs in significant patient population. If patient on clozapine develops tachycardia; first orthostasis, myocarditis and systemic infection should be ruled out. Tachycardia traditionally have been treated with B1 adrenergic blockers such as Atenolol. But the problem with beta blocker medications is that significant proportion develops hypotension.\n\nRecently developed Ivabradine slows heart rate via I(f) current, and is not associated with much cardiac adverse effects. Recent Clinical trials have been carried out to show its effects on Clozapine associated tachycardia which shows promising results. Some studies suggest using Ivabradine in patient population that have contraindication for beta blockers.\n\nAlthough both of these drugs are used widely in clinical practice, but as Ivabradine is relatively new drug there have been no head-to-head comparison with Atenolol. A recent meta-analysis tried to compare treatment efficacy in these patients, but found no studies that met their inclusion criteria. This current study attempts to make such comparison and guide further research.",[329,330,331,29],"Treatment Resistant Schizophrenia","Clozapine Adverse Reaction","Heart Rate Variability",[333,334,335],"Clozapine","Treatment resistant schizophrenia","heart rate variability","2024-07-11",{"date":338,"type":38},"2024-07-17",{"date":340,"type":38},"2023-08-01",{"date":342,"type":19},"2025-06-30",{"name":344,"class":81},"All India Institute of Medical Sciences, Bhubaneswar",{"id":346,"slug":4,"hasResults":10,"nctId":347,"briefTitle":348,"officialTitle":348,"acronym":4,"eligibilityCriteria":349,"healthyVolunteers":10,"sex":15,"minAge":350,"maxAge":351,"enrollmentInfo":352,"targetDuration":4,"studyType":54,"phases":354,"briefSummary":355,"conditions":356,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":364,"locationsCount":82},"100554300","NCT06497296","The Optimal Timing of the Initiation of Esophagogastroduodenoscopy After Oral Lidocaine Spray","Inclusion Criteria:\n\n* Eligible participants included patients aged ≥ 20 years who scheduled EGD from OPD for dyspepsia, peptic ulcer disease, GERD, subepithelial lesion evaluation, and diarrhea\n\nExclusion Criteria:\n\n* GI bleeding\n* endoscopic submucosal dissection due to prolonged scheduled procedure time\n* patients from emergency department or ward","20 Years","90 Years",{"count":353,"type":19},160,[56],"Esophagogastroduodenoscopy (EGD) is the main examination in the upper gastrointestinal field. Aspiration pneumonia may happen if choking occurs during the EGD insertion, and the exam quality and efficacy may be affected if gag reflex occurs. The endoscopist may terminate the exam to avoid complications if the patient could not obey the orders. To reach the high quality of EGD examination and to avoid possible complications, the patient's comfort and compliance during the EGD examination are important. Sedation using propofol can improve the patient's comfort and compliance. However, in patients unsuitable for systemic anesthesia, local lidocaine spray at pharynx is performed instead. Until now, there is no standardization of the waiting time between lidocaine spray and the initiation of EGD. This study aimed to investigate the optimal timing of the initiation of esophagogastroduodenoscopy after lidocaine spray.",[357,29],"Blood Pressure","2024-07-09",{"date":336,"type":38},{"date":361,"type":38},"2023-01-01",{"date":363,"type":19},"2024-12-31",{"name":365,"class":81},"National Cheng-Kung University Hospital",{"id":367,"slug":4,"hasResults":10,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":4,"eligibilityCriteria":371,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":372,"enrollmentInfo":373,"targetDuration":375,"studyType":21,"phases":4,"briefSummary":376,"conditions":377,"keywords":381,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":392,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":398,"locationsCount":82},"100313420","NCT03360227","Registry of Device Implantation","Registry of Device Implantation in University Hospital Duesseldorf","Inclusion Criteria:\n\n1. pre-operative clinical history taking\n2. pre-operative functional investigations (cardiac echo, electrocardiograms)\n3. pre-operative laboratory data evaluation (kidney function, liver function, biomarkers, thyroid hormone, CBC)\n\nExclusion Criteria:\n\n１. no written informed consent","80 Years",{"count":374,"type":19},2000,"24 Months","The implantable device therapy for cardiac arrhythmias has been an established therapy, and one of the common standard procedures in cardiac clinical practice.\n\nPacemakers, implantable cardioverter-defibrillators, and cardiac resynchronization therapy have been developed since 1960s, and the technologies in this field are still progressively developing. Not only these \"traditional\" implantable devices, there are multiple new devices for cardiac diseases, such as implantable loop recorder, vagal nerve stimulator and barostimulator.\n\nThe aim of this registry is to demonstrate the efficacy and the safety of standard device implantation procedures and to evaluate\u002F identify specific factors, including clinical characteristics, laboratory data and procedural data, which predict the prognosis\u002Fcomplication of the patients. These identification will result in further improvement of patients' care.",[161,28,29,378,379,380],"Sudden Cardiac Death","Ventricular Tachycardia","Ventricular Fibrillation",[382,383,384,385,386,387,388,389,390],"syncope","bradycardia","tachycardia","sudden cardiac death","implantable cardioverter-defibrillator","ventricular tachycardia","ventricular fibrillation","biomarker","thyroid hormone","2020-02-06",{"date":393,"type":38},"2020-02-07",{"date":395,"type":38},"2011-01",{"date":397,"type":19},"2030-12",{"name":399,"class":81},"Klinik für Kardiologie, Pneumologie und Angiologie",""]